Display options
Cite
Kim CW, Hong S, Oh SH, et al. Change of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients on Suppressive Levothyroxine Therapy for Differentiated Thyroid Carcinoma. J Bone Metab. 2015;22(3):135-41doi: 10.11005/jbm.2015.22.3.135.
Kim, C. W., Hong, S., Oh, S. H., Lee, J. J., Han, J. Y., Hong, S., Kim, S. H., Nam, M., & Kim, Y. S. (2015). Change of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients on Suppressive Levothyroxine Therapy for Differentiated Thyroid Carcinoma. Journal of bone metabolism, 22(3), 135-41. https://doi.org/10.11005/jbm.2015.22.3.135
Kim, Chei Won, et al. "Change of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients on Suppressive Levothyroxine Therapy for Differentiated Thyroid Carcinoma." Journal of bone metabolism vol. 22,3 (2015): 135-41. doi: https://doi.org/10.11005/jbm.2015.22.3.135
Kim CW, Hong S, Oh SH, Lee JJ, Han JY, Hong S, Kim SH, Nam M, Kim YS. Change of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients on Suppressive Levothyroxine Therapy for Differentiated Thyroid Carcinoma. J Bone Metab. 2015 Aug;22(3):135-41. doi: 10.11005/jbm.2015.22.3.135. Epub 2015 Aug 31. PMID: 26389089; PMCID: PMC4572035.
Copy Download .nbib Format: NLM
Share it on

J Bone Metab. 2015 Aug;22(3):135-41. doi: 10.11005/jbm.2015.22.3.135. Epub 2015 Aug 31.

Change of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients on Suppressive Levothyroxine Therapy for Differentiated Thyroid Carcinoma.

Journal of bone metabolism

Chei Won Kim, Seokbo Hong, Se Hwan Oh, Jung Jin Lee, Joo Young Han, Seongbin Hong, So Hun Kim, Moonsuk Nam, Yong Seong Kim

Affiliations

  1. Department of Endocrinology, Inha University School of Medicine, Incheon, Korea.
  2. Department of Endocrinology, Inha University School of Medicine, Incheon, Korea. ; Department of Internal Medicine, Hallym General Hospital, Incheon, Korea.

PMID: 26389089 PMCID: PMC4572035 DOI: 10.11005/jbm.2015.22.3.135

Abstract

Untreated hyperthyroidism and high-dose thyroid hormone are associated with osteoporosis, and increased bone mineral density (BMD) has been demonstrated in postmenopausal females with hypoparathyroidism. Studies on the effect of suppressive levothyroxine (LT4) therapy on BMD and bone metabolism after total thyroidectomy in patients with differentiated thyroid carcinoma have presented conflicting results, and few studies in relation to the status of hypoparathyroidism have been studied. One hundred postmenopausal women and 24 premenopausal women on LT4 suppression therapy were included in this study. BMD of lumbar spine and femur and bone turnover markers were measured at the baseline and during the follow-up period up to 18 months using dual energy X-ray absorptiometry. Biochemical marker of bone resorption was measured by urine deoxypyridinoline and bone formation by serum osteocalcin. The age ranged from 36 to 64 years old. Thyroid stimulating hormone (TSH) was suppressed during the study. The results showed that BMD of femur and lumbar spine were not significantly changed in both pre- and postmenopausal women except femur neck in postmenopausal women without hypoparathyroidism. Patients with hypoparathyroidism had higher BMD gain than those without hypoparathyroidism in total hip (1.25 vs. -1.18%, P=0.015). Biochemical markers of bone turnover, serum osteocalcin, and urine deoxypyridinoline did not show significant change. In conclusion, patients with well differentiated thyroid carcinoma are not at a great risk of bone loss after LT4 suppressive therapy. The state of hypoparathyroidism is associated with increased BMD, particularly in postmenopausal women.

Keywords: Bone density; Hypoparathyroidism; Postmenopause; Thyroid neoplasms; Thyroxine

References

  1. J Surg Res. 2010 Sep;163(1):69-71 - PubMed
  2. Ann Surg Treat Res. 2014 Feb;86(2):55-60 - PubMed
  3. J Clin Endocrinol Metab. 1990 Mar;70(3):766-70 - PubMed
  4. N Engl J Med. 1993 Feb 18;328(7):460-4 - PubMed
  5. Curr Opin Endocrinol Diabetes Obes. 2012 Dec;19(6):435-42 - PubMed
  6. Thyroid. 1998 Sep;8(9):737-44 - PubMed
  7. J Endocrinol. 1997 Sep;154 Suppl:S57-73 - PubMed
  8. Thyroid. 2009 Nov;19(11):1167-214 - PubMed
  9. Am J Clin Nutr. 2008 Aug;88(2):513S-519S - PubMed
  10. Osteoporos Int. 1998;8(4):311-6 - PubMed
  11. Theor Biol Med Model. 2007 Jun 09;4:23 - PubMed
  12. Curr Opin Endocrinol Diabetes Obes. 2014 Oct;21(5):405-8 - PubMed
  13. J Clin Endocrinol Metab. 2003 Jul;88(7):3155-9 - PubMed
  14. Bone. 2015 Feb;71:101-5 - PubMed
  15. J Clin Pharm Ther. 2004 Feb;29(1):1-5 - PubMed
  16. N Engl J Med. 1992 Dec 3;327(23 ):1637-42 - PubMed
  17. J Clin Endocrinol Metab. 1994 Apr;78(4):818-23 - PubMed
  18. Curr Med Res Opin. 2006 Jul;22(7):1369-73 - PubMed
  19. Endocrinol Metab Clin North Am. 1990 Mar;19(1):35-63 - PubMed
  20. J Clin Endocrinol Metab. 1996 Mar;81(3):1232-6 - PubMed
  21. Eur J Endocrinol. 2005 Jul;153(1):23-9 - PubMed
  22. J Clin Endocrinol Metab. 1996 Dec;81(12):4278-89 - PubMed
  23. J Clin Endocrinol Metab. 1999 Feb;84(2):718-22 - PubMed
  24. Endocr Relat Cancer. 2005 Dec;12 (4):973-81 - PubMed
  25. N Engl J Med. 1990 Sep 27;323(13):878-83 - PubMed
  26. J Musculoskelet Neuronal Interact. 2003 Mar;3(1):71-6 - PubMed

Publication Types